Viridian Therapeutics, Inc.\DE - 8-K Filing
On May 6, 2026, Viridian Therapeutics entered into an underwriting agreement for a $17.00 per share equity offering of 7,352,942 shares (plus an option to purchase up to 1,102,941 additional shares), generating net proceeds of approximately $117 million after expenses and discounts. On May 11, 2026, the company also completed a convertible notes offering for $250 million in aggregate principal amount (including an over-allotment option exercised in full) with terms including a 1.75% coupon rate, semiannual interest payments starting November 15, 2026, and conversion rights based on stock price... (Items: 1.01 Entry into a Material Definitive Agreement On May 11, 2026, Viridian Therapeutics, Inc, 2.03 Creation of a Direct Financial Obligation or an Off-Balance Sheet Arrangement, 8.01 Other Events Equity Offering On May 6, 2026, the Company entered into an underwriting agreement (the “Equity Underwriting Agreement”) with Je, 9.01 Financial Statements and Exhibits (d) Exhibits ExhibitNo)
Tickers: $VRDN